The Company’s updated corporate presentation provides updates with respect to INTERCEPT-AD, the Company’s Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease. The corporate presentation notes that the Company expects to complete enrollment in INTERCEPT-AD in the first quarter of 2023 and anticipates reporting topline data from this trial in the third quarter of 2023. The corporate presentation also notes that as of January 31, 2023, a total of 52 subjects have been randomized and dosed in Cohorts 1 through 6 of the clinical trial. Cohort 6 is fully enrolled, with planned doses of 60 mg/kg of ACU193 every four weeks.
In addition, the updated corporate presentation notes that on January 30, 2023, the Company submitted a protocol amendment to the U.S. Food and Drug Administration with respect to Cohort 7 of the clinical trial to reduce the dosage plan to 25 mg/kg every two weeks (updated from 60 mg/kg every two weeks). The proposed change was based in part on a blinded review of preliminary pharmacokinetic data, inclusive of plasma and cerebrospinal fluid levels, which indicated a dose of 60 mg/kg every two weeks should not be needed to attain central target engagement, and preliminary safety data, inclusive of two asymptomatic cases of ARIA-E (one in Cohort 4 after a single 60 mg/kg dose and one in Cohort 5 after a third 10 mg/kg dose).
Cautionary Note on Forward-Looking Statements
This Current Report contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing the Company’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “expects,” “anticipates,” “plans,” “potential” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning the Company’s plans with respect to completion of enrollment in its INTERCEPT-AD Phase 1 clinical trial and its expectations with regards to the timing of reporting topline data, the Company’s proposed protocol amendment, the Company’s expectations with respect to the therapeutic dose range of the Company’s product candidate, ACU193, and the therapeutic potential of ACU193, including its safety profile, potential for improved safety (including expected rate of ARIA) and efficacy, as well as the expectations concerning the INTERCEPT-AD trial. These statements are based upon the current beliefs and expectations of the Company’s management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of the COVID-19 pandemic. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission, including in Acumen’s Form 10-K for the year ended December 31, 2021, Acumen’s Form 10-Q for the quarter ended September 30, 2022, and future filings and reports by Acumen. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise. In this presentation, references to cash also include cash equivalents.